– USA, MA – TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Garry Nicholson to its Board of Directors.
The company also announced the appointment of current board member Dr. Stephen Biggar (M.D., Ph.D.) as Chair of the Board of Directors, succeeding Tim Barberich who has retired from the Board.
“We are pleased to welcome Garry to our Board of Directors. He has a breadth of experience in oncology development and commercialization spanning more than 35 years, including serving as president of Pfizer Oncology where he led its global oncology franchise. Garry has extensive expertise in operations, sales, regulatory strategy, and commercialization, and we look forward to working with him as we advance our clinical programs toward pivotal studies,” said CEO, Dr. Gavin MacBeath.
About Garry A. Nicholson
Garry Nicholson has more than 35 years of pharmaceutical and biotech oncology experience. Mr. Nicholson currently serves as chairman of the board of directors for G1 Therapeutics, Day One Biopharmaceuticals, and Abdera Therapeutics. He also previously served on the board of directors for Turning Point Therapeutics, Five Prime Therapeutics, Tmunity, and TESARO before their acquisitions by large pharmaceutical companies. As former president of Pfizer Oncology, his responsibilities included global commercialization, sales, clinical development, regulatory strategy, and business development for Pfizer’s oncology portfolio. Earlier in his career, Mr. Nicholson held various leadership positions in the oncology division of Eli Lilly and Company, including global oncology platform leader. He has also served as president and CEO of XTuit Pharmaceuticals.
“I am delighted to be joining TScan’s Board and look forward to working with the leadership team to further advance the progress of this company and its mission of bringing life-changing therapies to patients suffering from cancer. My previous experience across commercialization, operations, regulatory affairs and launch strategy will help support the growth of TScan and the advancement of this innovative pipeline,” said Garry Nicholson.
Mr. Nicholson earned a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)–engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing TCR-T candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex therapeutic TCR-Ts for patients with a variety of cancers.
For more: https://www.tscan.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.